Brain Tissue Collection for Neuropathological Studies

This study is currently recruiting participants. (see Contacts and Locations)
Verified January 2014 by National Institutes of Health Clinical Center (CC)
Sponsor:
Information provided by:
National Institutes of Health Clinical Center (CC)
ClinicalTrials.gov Identifier:
NCT00001260
First received: November 3, 1999
Last updated: March 14, 2014
Last verified: January 2014
  Purpose

The purpose of this study is to collect and study the brain tissue of deceased individuals to learn more about the nervous system and mental disorders. Information gained from donated tissue may lead to better treatments and potential cures for nervous system and mental disorders.

This study will ask relatives of deceased individuals to donate the brains of their deceased relatives to allow further study of neurological and psychiatric disorders. We do not accept prospective donations.


Condition
Bipolar Disorder
Depression
Anxiety Disorders
Schizophrenia
Tourette's Syndrome
Brain Diseases

Study Type: Observational
Official Title: Brain Procurement for the Human Brain Collection Core

Resource links provided by NLM:


Further study details as provided by National Institutes of Health Clinical Center (CC):

Estimated Enrollment: 2500
Study Start Date: May 1990
Detailed Description:

The knowledge of how affected tissue deviates from normal control tissue is an integral part of fully understanding a neurological or psychiatric disorder. The purpose of this protocol is to establish a coordinating program with the pathology departments of the Washington D.C. and metropolitan area hospitals and local medical examiner s offices for the donation of brain tissue.

Dissected brain tissue from selected brain regions, including but not limited to the dorsolateral prefrontal cortex and hippocampal formation, will be assembled from large cohorts of normal controls and schizophrenic subjects. The expression of mRNA and protein for selected molecules, chosen on the basis of their genetic association with schizophrenia, will be measured with a variety of assays including but not limited to qPCR and Western blots.

Outcome measures are the statistical comparison within normal controls of mRNA and/or protein levels in groups segmented by genotype. Similar comparisons will be made between schizophrenic cohorts and normal controls, in a diagnosis by genotype analysis with an ANOVA, or when appropriate an ANCOVA (controlling for variables such as age, race, gender, and postmortem interval).

  Eligibility

Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria
  • INCLUSION CRITERIA:

Brain tissue is needed from individuals suffering from a variety of neuropsychiatric disorders, especially schizophrenia, but also anxiety disorders, suicide, bipolar disorder, depression, Tourette s Syndrome, drug addictions (PCP, cocaine, alcohol, heroin or the like) and any form of dementia. In addition, brains from normal individuals without a history of neuropsychiatric disease will be needed for controls.

EXCLUSION CRITERIA:

No living subjects are enrolled in this protocol. Tissue is obtained after death, with the permission of next of kin, or from existing institutions with appropriate samples via an MTA or other applicable agreement.

Brain tissue is excluded from collection if there is a previously known history of strokes, lesions, or other major neuropathological abnormalities prior to the consenting process.

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00001260

Contacts
Contact: Barbara Lipska, M.D. (301) 496-9501 lipskab@intra.nimh.nih.gov

Locations
United States, District of Columbia
Office of the Chief Medical Examiner Recruiting
Washington, District of Columbia, United States, 20003
United States, Maryland
National Institutes of Health Clinical Center, 9000 Rockville Pike Recruiting
Bethesda, Maryland, United States, 20892
United States, Virginia
Office of the Chief Medical Examiner Recruiting
Fairfax, Virginia, United States, 22032
Sponsors and Collaborators
Investigators
Principal Investigator: Barbara Lipska, M.D. National Institute of Mental Health (NIMH)
  More Information

Additional Information:
Publications:
ClinicalTrials.gov Identifier: NCT00001260     History of Changes
Other Study ID Numbers: 900142, 90-M-0142
Study First Received: November 3, 1999
Last Updated: March 14, 2014
Health Authority: United States: Federal Government

Keywords provided by National Institutes of Health Clinical Center (CC):
Schizophrenia
Neuropathology
Neurochemistry
Substance Abuse
Bipolar Disorder
Aging
Normal Development
Depression
Anxiety Disorders
Suicide
Dementia
Neuropsychiatric Disorders
Tourette's Syndrome
Normal Controls

Additional relevant MeSH terms:
Brain Diseases
Anxiety Disorders
Bipolar Disorder
Depression
Depressive Disorder
Disease
Schizophrenia
Syndrome
Tourette Syndrome
Affective Disorders, Psychotic
Basal Ganglia Diseases
Behavioral Symptoms
Central Nervous System Diseases
Genetic Diseases, Inborn
Heredodegenerative Disorders, Nervous System
Mental Disorders
Mental Disorders Diagnosed in Childhood
Mood Disorders
Movement Disorders
Nervous System Diseases
Neurodegenerative Diseases
Pathologic Processes
Schizophrenia and Disorders with Psychotic Features
Tic Disorders

ClinicalTrials.gov processed this record on October 20, 2014